biostudies-literatureUnknown8Sarda-Mantel LMinistère des Affaires Sociales, de la Santé et des Droits des Femmes<b>Objective:</b> In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [¹⁸F]FDG-PET for this purpose. <b>Methods:</b> Forty-two patients out of 55 included patients could be analyzed. Additionally to usual biological, histological and morphological explorations, [¹⁸F]FDG-PET was performed at diagnosis (PET1), at the end of treatment (PET2), indeed 6 months later. Then patients were followed until 12 months after end of prescribed treatment. <b>Results:</b> PET1 was positive in 97.6% of patients and discovered unknown injured sites in 52.7% of cases. PET2 was positive in 83.3% of uncured patients, and in 82.3% of cured patients. The sum and mean value of SUV_max measured in PET/CT lesions decreased between PET1 and PET2 in all patients. Mean value of SUV_max (MSUV) and sum value of SUVmax on PET2 showed the highest AUC on ROC curves for the diagnosis of healing at the end of prescribed treatment; MSUV 3.5 on PET2 had a sensitivity of 76.5% and a specificity of 80.0% to affirm healing at the end of prescribed treatment. <b>Conclusions:</b> [¹⁸F]FDG-PET/CT was useful at diagnosis, discovering unknown lesions in 52.7% of cases. MSUV on PET2 was the best criteria to affirm healing at the end of prescribed treatment.Frontiers in medicine715115https://www.ebi.ac.uk/biostudies/studies/S-EPMC8416085biostudies-literature[ ^<i>18</i> F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis.PMC8416085Durand ERioux CSarda-Mantel LLopes AMontravers FDeradji OPaycha FMikail NGoulenok TPonscarme DMechai FAlfaiate TNagat SLYeni PSoussan MLaouenan CKaoutar JLemarignier CBenali Kfalse[ ^<i>18</i> F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis.<b>Objective:</b> In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [¹⁸F]FDG-PET for this purpose. <b>Methods:</b> Forty-two patients out of 55 included patients could be analyzed. Additionally to usual biological, histological and morphological explorations, [¹⁸F]FDG-PET was performed at diagnosis (PET1), at the end of treatment (PET2), indeed 6 months later. Then patients were followed until 12 months after end of prescribed treatment. <b>Results:</b> PET1 was positive in 97.6% of patients and discovered unknown injured sites in 52.7% of cases. PET2 was positive in 83.3% of uncured patients, and in 82.3% of cured patients. The sum and mean value of SUV_max measured in PET/CT lesions decreased between PET1 and PET2 in all patients. Mean value of SUV_max (MSUV) and sum value of SUVmax on PET2 showed the highest AUC on ROC curves for the diagnosis of healing at the end of prescribed treatment; MSUV 3.5 on PET2 had a sensitivity of 76.5% and a specificity of 80.0% to affirm healing at the end of prescribed treatment. <b>Conclusions:</b> [¹⁸F]FDG-PET/CT was useful at diagnosis, discovering unknown lesions in 52.7% of cases. MSUV on PET2 was the best criteria to affirm healing at the end of prescribed treatment.2021-01-01T00:00:00Z20212024-11-12T17:23:12.505Z2022-02-11T10:17:56.362ZS-EPMC84160853448534510.3389/fmed.2021.715115